HIMS — Hims & Hers Health Inc
NYSE · Health Care · Health Care
- Latest Close
- $28.15
- 30-Day Move
- -24.3%
- Market Cap
- $4.2B
- Shares Outstanding
- 227,940,000
- P/E Ratio
- 32.74
- P/B Ratio
- 13.66
Peers: BLLN, CHE, CRVL, CVS, HNGE, LFST
Analyst consensus: — · Target $0.51
Hims & Hers Health Inc
A read-only Alphactor snapshot forHims & Hers Health Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-23
Topline snapshot
Latest Close
$28.15
30-Day Move
-24.3%
Market Cap
$4.2B
Shares Outstanding
227,940,000
P/E Ratio
32.74
P/B Ratio
13.66
$28.15
-24.3%last 90 delayed daily bars
90D High
$38.88
90D Low
$13.74
Avg Volume
31,172,007
Gross margin is running at 73.8%, which gives a quick read on operating quality before you open the full model.
Net margin is 5.5%, useful for comparing HIMS against peers in Health Care.
HIMS is down 24.3% over the last 30 trading days shown on this page.
Latest operating income is $9M, which helps anchor the headline ratios with an actual earnings figure.
Composite Fair Value
$32.04
Rule of 40
61.4%
Latest Close
$28.15
30-Day Move
-24.3%
Market Cap
$4.2B
Shares Outstanding
227,940,000
P/E Ratio
32.74
P/B Ratio
13.66
ROE
23.7%
ROA
6.0%
Gross Margin
73.8%
Operating Margin
4.5%
Net Margin
5.5%
Debt / Equity
1.8
Current Ratio
1.9
Latest Revenue
$618M
Revenue
$618M
Gross Profit
$444M
Operating Income
$9M
Net Income
$21M
Gross Margin
7384.0%
Net Margin
547.0%
Current Ratio
1.90
Debt / Equity
1.80
Fair Value
$32.04
Upside / Downside
+13.8%
Signal
Fairly Valued
Implied Growth
27.4%
DCF
$16.49
EV/Rev
$47.58
Growth Assumption
50.0%
Discount Rate
9.4%
Terminal Growth
2.0%
Base FCF
$57M
Valuation spread
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
High growth priced in
Altman Z
2.94
Grey
Piotroski
4
Moderate (4-6)
Cash Conversion
2.34x
Rule of 40
61.4%
Elite
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $527M | $-69M | $-66M | $-34M |
| 2023-12-31 | $872M | $-29M | $-24M | $47M |
| 2024-12-31 | $1.5B | $62M | $126M | $198M |
| 2025-12-31 | $2.3B | $106M | $128M | $57M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
| Date | EPS Est. | EPS Act. | Surprise | 1D Move |
|---|---|---|---|---|
| 2026-02-23 | 0.05 | 0.08 | +71.3% | -0.3% |
Qube Research & Technologies
Filed 2025-08-14
--
--
Two Sigma Advisers
Filed 2025-11-14
--
--
Vanguard Group
Filed 2025-11-07
$1.1B
+4.5%
Farallon Capital
Filed 2026-02-17
$610M
--
Renaissance Technologies
Filed 2025-11-13
$516M
+32.4%
Citadel Advisors
Filed 2025-11-14
$367M
--
Goldman Sachs
Filed 2026-02-10
$362M
+16.5%
—
Consensus
—$0.51
—
—
—
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Healthcare Investing: Pharma, Biotech, and the FDA Calendar
A framework for navigating healthcare stocks across pharma, biotech, and medical devices, with emphasis on regulatory catalysts and pipeline valuation.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.